Loading cancer entity…
Loading cancer entity…
Clinical trials
55 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00314119 | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | completed | — | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01362803 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | active not recruiting | Phase 1 / Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06175637 | Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs |
Data updated 22 hours agoSource updated Sep 28, 2026source: clinicaltrials
| active not recruiting |
| — |
| 409 |
| AstraZenecaINDUSTRY |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06515860 | Neurofibromatosis Type 1 Tumor Early Detection Study(NF1-TED) | enrolling by invitation | — | 1,000 | David MillerOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06360406 | Real-World Treatment Study of Koselugo (Selumetinib) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06502171 | Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas(NF113) | recruiting | Phase 1 | 30 | Girish Dhall, MDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04590235 | A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | active not recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06880991 | Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study | recruiting | — | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03962543 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas(ReNeu) | active not recruiting | Phase 2 | 114 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05891847 | Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | terminated | — | 150 | AstraZenecaINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06188741 | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1(NF114) | recruiting | Phase 2 | 200 | University of Alabama at BirminghamOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07407803 | Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas | recruiting | Phase 3 | 177 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | recruiting | Phase 1 | 10 | Johns Hopkins UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03363217 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | active not recruiting | Phase 2 | 114 | St. Justine's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06300502 | Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) | enrolling by invitation | Phase 1 | 15 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04924608 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas(KOMET) | active not recruiting | Phase 3 | 145 | AstraZenecaINDUSTRY | 13 | Mar 23, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT05581511 | Natural History Study of Cutaneous Neurofibromas in People With NF1(cNF Natural Hx) | active not recruiting | — | 500 | Johns Hopkins UniversityOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | not yet recruiting | Phase 1 / Phase 2 | 65 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT03231306 | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas(NF108-BINI) | completed | Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05913037 | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | active not recruiting | Phase 3 | 167 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04730583 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT03531814 | Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials | completed | N/A | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05438290 | DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | completed | Phase 1 | 17 | Nicholas GulatiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06379230 | A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | unknown | — | 2,000 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03741101 | Treatment of NF1-related Plexiform Neurofibroma With Trametinib(plexifpc) | unknown | Phase 2 | 15 | Region SkaneOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03326388 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours(INSPECT) | completed | Phase 1 / Phase 2 | 14 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05199376 | Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1(CryoNF1) | recruiting | N/A | 30 | Centre Leon BerardOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT01800032 | PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) | completed | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03820778 | Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | active not recruiting | N/A | 10 | Children's National Research InstituteOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT03688568 | Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT03027401 | Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | withdrawn | — | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01347307 | Stereotactic Body Radiotherapy for Spine Tumors | completed | N/A | 38 | Mercy ResearchOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT00727233 | Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00076102 | Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00021541 | R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 2 | Apr 17, 2018 | clinicaltrials |
| NCT00396019 | Study of PEG-Intron for Plexiform Neurofibromas | completed | Phase 2 | 86 | University of PittsburghOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03090971 | Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | completed | Phase 2 | 7 | Fundação Educacional Serra dos ÓrgãosOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT00326872 | AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | terminated | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01140360 | Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas(0908-09) | completed | Phase 1 / Phase 2 | 21 | Kent RobertsonOTHER | 1 | Jul 2, 2017 | clinicaltrials |